Novo’s Ozempic copy 15% cheaper, but Discovery still won’t change its position
Novo Nordisk’s Extensior launches in SA on 31 July at a 15% discount, but Discovery Health says it is still not enough to expand medical-scheme funding.
As it rages, the semaglutide debate exposes public trust deficit in healthcare
A Mail & Guardian opinion piece: the SA semaglutide debate is at heart a crisis of public trust in the institutions responsible for health.
Dozen weight-loss generics being reviewed for SA
SAHPRA is reviewing 12 generic semaglutide applications after Novo Nordisk’s SA patent expired, with more approvals expected to widen access.
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!